Agarose-Anti-HA-Tag poab 50uL  Trial Size

  • Applications
    • IP
  • Target HA
  • Host Species Rabbit
  • Code # 561-8B
  • Size 50 μl
  • Price
    $110.84
Specifications

Background

Epitope tagging has widely been accepted technique that fuse an epitope peptide to a certain protein as a marker for gene expression. With this technique, the gene expression can be easily monitored on western blotting, immunoprecipitation and immunofluorescence utilizing with an antibody that recognizes such an epitope. Amino acid sequences that are widely used for the epitope tagging are as follow; YPYDVPDYA (HA-Tag), EQKLISEEDL (Myc-Tag) and YTDIEMNRLGK (VSV-G-Tag), which corresponding to the partial peptide of Influenza hemagglutinin protein, human c-myc gene product and Vesicular stomatitis virus glycoprotein respectively.
  • Antibody Type:
    Polyclonal
  • Application:
    IP
  • Conjugate:
    Agarose
  • Description:

    Polyclonal antibody of 50 μL targeting HA for IPP.

    For additional information, please see datasheet for standard vial.

  • Formulation:
    540 mg of anti-HA Tag polyclonal antibody covalently coupled to 200 mL of agarose gel and provided as a 50% gel slurry suspended in PBS containing preservative (0.09% sodium azide) for a total volume of 400 mL.
  • Host Species:
    Rabbit
  • Immunogen:
    YPYDVPDYA (HA-tag)-KLH
  • Isotype:
    IgG
  • Product Type:
    Antibody
  • Reactivity:
    This antibody recognizes HA-tagpeptide sequence (YPYDVPDYA) onImmunoprecipitation.
  • Research Area:
    Epitope Tag
  • Short Description:
    HA Polyclonal Antibody.
  • Size:
    50 μl
  • Storage Temperature:
    4°C
  • Target:
    HA
Citations
  1. Chen G et al. Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol. 202, 321-9 (2004),
  2. Glatt SJ et al. Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. PNAS 102, 15533-8 (2005),
  3. Huang KC et al. Selenium binding protein 1 in ovarian cancer. Int J Cancer 118, 2433-40 (2006),
  4. Kim H et al. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 6, 3466-76 (2006),
  5. Li T et al. Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Mol Nutr Food Res. 52, 1289-99 (2008),
  6. Raucci R et al. Structural and functional studies of the human selenium binding protein-1 and its involvement in hepatocellular carcinoma. Biochim Biophys Acta 1814, 513-22 (2011),
  7. Silvers AL et al. Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity. Clin Cancer Res 16, 2009-21 (2010),
  8. Stammer K et al. Selenium-Binding Protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer. Gynecol Oncol. 109, 115-21 (2008),
  9. Zhang C et al. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma. Hum Pathol. 41, 255-61 (2010),
  10. Zhang S et al. Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium. PLoS One 8, e63702 (2013)